BackLyell Immunopharma Overview

Lyell Immunopharma Current Assets

Track Lyell Immunopharma's current assets ($190M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$186.21M
↓ 43.26% YoYΔ $-141.99M vs prior year quarter

Peer trimmed avg / median

Loading

Lyell Immunopharma Current Assets History

Loading

Lyell Immunopharma vs. peers: Current Assets Comparison

Loading

Lyell Immunopharma Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Lyell Immunopharma (LYEL) FAQ

As of the most recent data (September 2026), LYEL shows a current assets of $190M. That compares with $330M in the prior-year period — down 43.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LYEL's current assets is now $190M (was $330M) — a 43.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Lyell Immunopharma is outperforming or lagging.

Tracking LYEL's current assets over time shows whether Lyell Immunopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $190M That compares with $330M in the prior-year period — down 43.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has Lyell Immunopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $190M) with ownership activity and broader fundamentals.

Lyell Immunopharma's current assets is $190M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.